HINGHAM, Mass., December 27, 2021 (GLOBE NEWSWIRE) – Microbot Medical Inc. (Nasdaq: MBOT) has announced that it has entered into a strategic collaboration agreement with Stryker, one of the world’s leading medical technology companies. The company will work with Stryker’s Neurovascular division to integrate its neurovascular instruments with Microbot’s LIBERTY robotic system to develop the world’s first dedicated robotic procedure kits for use in certain neurovascular procedures.

“We have already ensured that the LIBERTY robotic system has a strong and sustainable competitive advantage, and the collaboration with Stryker will allow us to further develop in the neurovascular space,” commented Harel Gadot, Chief Executive Officer and President by Microbot Medical. “I believe the similarities in our culture of innovation, along with our complementary core capabilities, will allow us to establish a truly differentiated solution that will benefit all stakeholders and accelerate our goal of changing the way robotic surgery is considered and adopted. “

The company will continue to independently develop the LIBERTY robotic system for use in peripheral and coronary procedures. Animal feasibility studies to date support the company’s claim that this will potentially allow physicians to safely and effectively perform vascular catheter procedures from a distance, and reduce the risk of radiation exposure. , physical strain on the user and nosocomial infections (HAI), without the need for bulky and expensive capital equipment.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a preclinical medical device company specializing in transformational micro-robotic technologies, focusing primarily on the natural and artificial lights of the human body. Microbot’s current proprietary technology platforms form the basis for the development of a Multi-Generation Pipeline Portfolio (MGPP).

Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham and Yossi Bornstein with the aim of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. More information on Microbot Medical is available at http://www.microbotmedical.com.

The story continues

Safe harbor

Statements relating to the collaboration between the Company and Stryker, the advancement of the LIBERTY robotic system covered by the collaboration agreement and the potential benefits of such collaboration and statements relating to future financial and / or operational results, future growth research, technology, development and potential opportunities for Microbot Medical Inc. and its subsidiaries, as well as other statements regarding the expectations, beliefs, objectives, plans or future prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. of 1995 and federal securities laws. All statements which are not historical facts (including, but not limited to, statements which contain words such as “will”, “believes”, “plans”, “anticipates”, “expects” “And” estimates “) should also be considered as forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the development and / or commercialization of potential products, including LIBERTY and SCS, the result of its studies to assess LIBERTY, SCS and other technologies, uncertainty in the results of preclinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to raise future capital and sustain intellectual property rights. Additional information on the risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the website of the SEC at www.sec.gov. Microbot Medical disclaims any intention or obligation to update these forward-looking statements, except as required by law.

Investor contact:

Michel Polyviou
EVC Group
[email protected]
732-933-2754